<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Osteopore Ltd — News on 6ix</title>
<link>https://6ix.com/company/osteopore-ltd</link>
<description>Latest news and press releases for Osteopore Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 02:53:17 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/osteopore-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836691778dffbe2df15efa4.webp</url>
<title>Osteopore Ltd</title>
<link>https://6ix.com/company/osteopore-ltd</link>
</image>
<item>
<title>Activities Report March 2026 and Appendix 4C</title>
<link>https://6ix.com/company/osteopore-ltd/news/activities-report-march-2026-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/activities-report-march-2026-and-appendix-4c</guid>
<pubDate>Thu, 30 Apr 2026 02:53:17 GMT</pubDate>
<description>Activities Report March 2026 and Appendix 4C</description>
</item>
<item>
<title>Further Drawdown of T2 of the Redeemable Convertible Notes</title>
<link>https://6ix.com/company/osteopore-ltd/news/further-drawdown-of-t2-of-the-redeemable-convertible-notes</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/further-drawdown-of-t2-of-the-redeemable-convertible-notes</guid>
<pubDate>Thu, 26 Mar 2026 11:56:04 GMT</pubDate>
<description>Further Drawdown of T2 of the Redeemable Convertible Notes</description>
</item>
<item>
<title>Clarification - agreement for injectable regen bone filler</title>
<link>https://6ix.com/company/osteopore-ltd/news/clarification-agreement-for-injectable-regen-bone-filler</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/clarification-agreement-for-injectable-regen-bone-filler</guid>
<pubDate>Thu, 12 Mar 2026 11:55:04 GMT</pubDate>
<description>Clarification - agreement for injectable regen bone filler</description>
</item>
<item>
<title>OSX signs agreement for injectable regenerative bone filler</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-signs-agreement-for-injectable-regenerative-bone-filler</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-signs-agreement-for-injectable-regenerative-bone-filler</guid>
<pubDate>Thu, 12 Mar 2026 02:48:04 GMT</pubDate>
<description>OSX signs agreement for injectable regenerative bone filler</description>
</item>
<item>
<title>OSX secures distribution for autologous dentin bone graft</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-secures-distribution-for-autologous-dentin-bone-graft</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-secures-distribution-for-autologous-dentin-bone-graft</guid>
<pubDate>Tue, 03 Mar 2026 03:43:18 GMT</pubDate>
<description>OSX secures distribution for autologous dentin bone graft</description>
</item>
<item>
<title>Appendix 4E Preliminary Final Report</title>
<link>https://6ix.com/company/osteopore-ltd/news/appendix-4e-preliminary-final-report-87</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/appendix-4e-preliminary-final-report-87</guid>
<pubDate>Fri, 27 Feb 2026 13:03:13 GMT</pubDate>
<description>Appendix 4E Preliminary Final Report</description>
</item>
<item>
<title>Drawdown of Tranche 2 of the Redeemable Convertible Notes</title>
<link>https://6ix.com/company/osteopore-ltd/news/drawdown-of-tranche-2-of-the-redeemable-convertible-notes</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/drawdown-of-tranche-2-of-the-redeemable-convertible-notes</guid>
<pubDate>Mon, 16 Feb 2026 13:30:08 GMT</pubDate>
<description>Drawdown of Tranche 2 of the Redeemable Convertible Notes</description>
</item>
<item>
<title>OSX secures Latin America deal for craniofacial distribution</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-secures-latin-america-deal-for-craniofacial-distribution</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-secures-latin-america-deal-for-craniofacial-distribution</guid>
<pubDate>Fri, 13 Feb 2026 03:18:14 GMT</pubDate>
<description>OSX secures Latin America deal for craniofacial distribution</description>
</item>
<item>
<title>Further Drawdown of T1 of the Redeemable Convertible Notes</title>
<link>https://6ix.com/company/osteopore-ltd/news/further-drawdown-of-t1-of-the-redeemable-convertible-notes</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/further-drawdown-of-t1-of-the-redeemable-convertible-notes</guid>
<pubDate>Fri, 06 Feb 2026 13:05:10 GMT</pubDate>
<description>Further Drawdown of T1 of the Redeemable Convertible Notes</description>
</item>
<item>
<title>Activities Report December 2025 and Appendix 4C</title>
<link>https://6ix.com/company/osteopore-ltd/news/activities-report-december-2025-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/activities-report-december-2025-and-appendix-4c</guid>
<pubDate>Fri, 30 Jan 2026 03:46:09 GMT</pubDate>
<description>Activities Report December 2025 and Appendix 4C</description>
</item>
<item>
<title>Clarification - agreement for orthopaedic products in HK</title>
<link>https://6ix.com/company/osteopore-ltd/news/clarification-agreement-for-orthopaedic-products-in-hk</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/clarification-agreement-for-orthopaedic-products-in-hk</guid>
<pubDate>Thu, 22 Jan 2026 11:45:07 GMT</pubDate>
<description>Clarification - agreement for orthopaedic products in HK</description>
</item>
<item>
<title>OSX strikes agreement for orthopaedic products in Hong Kong</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-strikes-agreement-for-orthopaedic-products-in-hong-kong</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-strikes-agreement-for-orthopaedic-products-in-hong-kong</guid>
<pubDate>Thu, 22 Jan 2026 03:42:05 GMT</pubDate>
<description>OSX strikes agreement for orthopaedic products in Hong Kong</description>
</item>
<item>
<title>Clarification - OSX partner Chinese dental & maxillofacial</title>
<link>https://6ix.com/company/osteopore-ltd/news/clarification-osx-partner-chinese-dental-and-maxillofacial</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/clarification-osx-partner-chinese-dental-and-maxillofacial</guid>
<pubDate>Fri, 16 Jan 2026 09:09:11 GMT</pubDate>
<description>Clarification - OSX partner Chinese dental & maxillofacial</description>
</item>
<item>
<title>OSX partners up for Chinese dental & maxillofacial market</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-partners-up-for-chinese-dental-and-maxillofacial-market</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-partners-up-for-chinese-dental-and-maxillofacial-market</guid>
<pubDate>Fri, 16 Jan 2026 02:41:04 GMT</pubDate>
<description>OSX partners up for Chinese dental & maxillofacial market</description>
</item>
<item>
<title>OSX partners DKSH for dental products in Malaysia</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-partners-dksh-for-dental-products-in-malaysia</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-partners-dksh-for-dental-products-in-malaysia</guid>
<pubDate>Tue, 25 Nov 2025 02:49:18 GMT</pubDate>
<description>OSX partners DKSH for dental products in Malaysia</description>
</item>
<item>
<title>Kelyniam Global Secures Exclusive U.S. License for Evonik's VESTAKEEP® Fusion Biomaterial in Cranial Implants</title>
<link>https://6ix.com/company/osteopore-ltd/news/kelyniam-global-secures-exclusive-us-license-for-evoniks-vestakeepr-fusion-biomaterial-in-cranial-implants-2</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/kelyniam-global-secures-exclusive-us-license-for-evoniks-vestakeepr-fusion-biomaterial-in-cranial-implants-2</guid>
<pubDate>Thu, 13 Nov 2025 17:47:00 GMT</pubDate>
<description>CANTON, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today announced it has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material, for cranial, craniofacial, and maxillofacial implants. This agreement grants Kelyniam two years of exclusivity with the option for renewal upon mutual agreement. The license enhances Kelyniam's regenerati</description>
</item>
<item>
<title>Activities Report September 2025 and Appendix 4C</title>
<link>https://6ix.com/company/osteopore-ltd/news/activities-report-september-2025-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/activities-report-september-2025-and-appendix-4c</guid>
<pubDate>Fri, 31 Oct 2025 02:50:14 GMT</pubDate>
<description>Activities Report September 2025 and Appendix 4C</description>
</item>
<item>
<title>OSX collaborates with TTSH to develop novel implant for AVN</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-collaborates-with-ttsh-to-develop-novel-implant-for-avn</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-collaborates-with-ttsh-to-develop-novel-implant-for-avn</guid>
<pubDate>Tue, 09 Sep 2025 02:58:19 GMT</pubDate>
<description>OSX collaborates with TTSH to develop novel implant for AVN</description>
</item>
<item>
<title>OSX Invests AUD 0.5m in Cellular Regenerative Medicine</title>
<link>https://6ix.com/company/osteopore-ltd/news/osx-invests-aud-05m-in-cellular-regenerative-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/osx-invests-aud-05m-in-cellular-regenerative-medicine</guid>
<pubDate>Mon, 01 Sep 2025 02:47:25 GMT</pubDate>
<description>OSX Invests AUD 0.5m in Cellular Regenerative Medicine</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/osteopore-ltd/news/half-yearly-report-and-accounts-475</link>
<guid isPermaLink="true">https://6ix.com/company/osteopore-ltd/news/half-yearly-report-and-accounts-475</guid>
<pubDate>Fri, 29 Aug 2025 11:39:19 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
</channel>
</rss>